A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : VCM / vacuous chewing movements

[Related PubMed/MEDLINE]
Total Number of Papers: 46
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   VCM  (>> Co-occurring Abbreviation)
Long Form:   vacuous chewing movements
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Investigation of the effects of cannabidiol on vacuous chewing movements, locomotion, oxidative stress and blood glucose in rats treated with oral haloperidol. CBD, TD
2018 Gabapentin reduces haloperidol-induced vacuous chewing movements in mice. GABA, GAD, TD, TH
2018 L-Theanine Decreases Orofacial Dyskinesia Induced by Reserpine in Rats. FT, LPO, LT, OD, RES, TD, TP
2018 Protective Effect of L-Theanine on Haloperidol-Induced Orofacial. FT, HAL, LPO, LT, OD, TD, TP
2017 Angiotensin II type 1/adenosine A 2A receptor oligomers: a novel target for tardive dyskinesia. A2AR, AT1R, D2Rs, TD
2015 (-) Epigallocatechin-3-gallate attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. EGCG, FT, LPO, OD, TD, TP
2015 Effect of ethanolic extract of Coriandrum sativum L. on tacrine induced orofacial dyskinesia. CAT, GSH, LPO, OB, SOD, TP
2014 Danggui-shaoyao-san, a traditional Chinese medicine prescription, alleviates the orthodontic pain and inhibits neuronal and microglia activation. DSS, ETM, POD, TCM
2013 Comparative extrapyramidal effects of Rauwolfia vomitoria, chlorpromazine and reserpine in mice. CPZ, RES, RV
10  2012 Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system. YKS
11  2012 Protective Effect of Leaves of Murraya koenigii on Reserpine-Induced Orofacial Dyskinesia. CAT, GSH, LPO, MEMK, OB, SOD, TP
12  2011 Beneficial effects of an innovative exercise model on motor and oxidative disorders induced by haloperidol in rats. DA, OS
13  2011 The styrene metabolite, phenylglyoxylic acid, induces striatal-motor toxicity in the rat: influence of dose escalation/reduction over time. HP, PGA
14  2007 Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats. BEL, iPLA2, MAFP
15  2006 Effects of baclofen on reserpine-induced vacuous chewing movements in mice. ---
16  2006 Effects of diphenyl-diselenide on orofacial dyskinesia model in rats. FT, TP
17  2005 Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. MP, OLZ, s.c, VEH
18  2005 Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. PLC
19  2004 Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. DA, ESR, HP, PBN, TD
20  2004 Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. DCS, Gly, TD
21  2003 Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats. TD
22  2003 Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. ---
23  2003 Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia. PLG, TD
24  2003 Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. SOD
25  2003 Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. NO, TD
26  2002 Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice. ---
27  2002 The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? HAL, TD
28  2001 Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. ---
29  2000 No changes in dopamine D(1) receptor mRNA expressing neurons in the dorsal striatum of rats with oral movements induced by long-term haloperidol administration. ---
30  1999 Neurochemical changes in the entopeduncular nucleus and increased oral behavior in rats treated subchronically with clozapine or haloperidol. ---
31  1998 Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. ---
32  1997 Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity. HAL
33  1996 High frequency oral movements induced by long-term administration of amperozide but not FG5803 in rats. TP, TR
34  1996 Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. TD
35  1995 The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia? 3-NP, TD
36  1995 The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment. HAL, TD
37  1994 GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. TD
38  1994 Quantitative autoradiography of striatal dopamine D1, D2 and re-uptake sites in rats with vacuous chewing movements. ---
39  1994 Tardive dyskinesia: behavioral effects of repeated intracerebroventricular haloperidol injections in rats do not confirm the kindling hypothesis. i.c.v, TD
40  1994 The relationship between motor effects in rats following acute and chronic haloperidol treatment. TD
41  1993 Intranigral stimulation of oral movements by [Pro9] substance P, a neurokinin-1 receptor agonist, is enhanced in chronically neuroleptic-treated rats. NK-1
42  1993 Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function. DA
43  1991 Development of vacuous chewing movements in rats: role of housing environment. ---
44  1991 Intranigral tachykinin NK3 receptor agonist elicits oral movements in rats. ---
45  1990 Effect of a dopamine D-1 agonist in rats treated chronically with zuclopenthixol. CTRL, DISC, ZU
46  1990 Methylazoxymethanol (MAM)-induced brain lesion and oral dyskinesia in rats. GAD, MAM